他汀类药物使用与多发性骨髓瘤生存改善相关:瑞典4315例人群研究
该研究基于瑞典全国健康登记数据,纳入2007至2013年确诊的4315例多发性骨髓瘤患者,评估他汀使用与剂量强度同骨髓瘤特异性及全因死亡的关系。结果显示他汀使用与骨髓瘤特异性死亡风险降低相关,且强度分析提示剂量反应趋势,但高强度治疗者较少。
要点
- 他汀使用与骨髓瘤特异性死亡风险降低相关,全因死亡关联较弱。
- 诊断后6个月内他汀使用多变量校正HR为0.73(95%CI 0.60-0.89)。
- 强度分析提示剂量反应趋势,但高强度治疗者较少且趋势多不显著。
核心结论
- 在这项大型人群队列中,他汀使用与男女多发性骨髓瘤患者骨髓瘤特异性生存改善相关。
研究设计与样本
- 以诊断作为基线计算生存时间,采用Cox回归计算暴露相关骨髓瘤特异性及全因死亡的风险比(HR)和95%置信区间(CI)。
- 另采用巢式病例对照分析评估整个随访期间他汀暴露与骨髓瘤特异性死亡风险。
- 他汀剂量强度按美国心脏病学会/美国心脏协会推荐分类。
主要发现
- 他汀使用与骨髓瘤特异性死亡风险降低相关:诊断前使用多变量校正HR 0.83(95%CI 0.71-0.96),诊断后6个月HR 0.73(95%CI 0.60-0.89),整个随访期HR 0.65(95%CI 0.52-0.80)。
- 他汀使用与全因死亡的关联较弱。
- 强度分析提示剂量反应:诊断后6个月低强度HR 0.76(95%CI 0.56-1.03),中强度HR 0.73(95%CI 0.58-0.92),高强度HR 0.33(95%CI 0.08-1.32)。
- 接受高强度治疗的患者相对较少,且趋势仅在诊断前未校正使用中具有统计学显著性。
关键数值与推荐
- 他汀剂量强度分类依据美国心脏病学会/美国心脏协会推荐。
- 骨髓瘤特异性死亡多变量校正HR:诊断前0.83(95%CI 0.71-0.96),诊断后6个月0.73(95%CI 0.60-0.89),整个随访期0.65(95%CI 0.52-0.80)。
- 诊断后6个月骨髓瘤特异性死亡HR:低强度0.76(95%CI 0.56-1.03),中强度0.73(95%CI 0.58-0.92),高强度0.33(95%CI 0.08-1.32)。
临床怎么用
- 他汀使用与骨髓瘤患者骨髓瘤特异性生存改善相关,但当前证据来自观察性研究,不能据此推荐他汀作为骨髓瘤辅助治疗。
- 需随机前瞻性研究评估他汀作为骨髓瘤辅助治疗的价值。
局限性
- 接受高强度他汀治疗的患者相对较少。
- 剂量反应趋势仅在诊断前未校正使用中具有统计学显著性。
- 研究为观察性设计,不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Statin use has been associated with reduced cancer-specific mortality among patients with several cancer types, including multiple myeloma (MM). We aimed to further elucidate the association of statin use and dose intensity with MM survival. Using Swedish population-based national health registers, we identified all incident MM diagnoses occurring January 1, 2007 to December 31, 2013 and their drug dispensations and comorbidities. We assessed statin exposure in 6-month periods pre- and post-diagnosis, treated diagnosis as baseline for calculating survival time, and calculated hazard ratios (HR) and 95% confidence intervals (CI) of exposure-related MM-specific and all-cause mortality using Cox regression. We assessed statin exposure during the entire follow-up and risk of MM-specific mortality in a nested case-control analysis. We classified dose intensity according to American College of Cardiology/American Heart Association recommendations. We ascertained 4315 MM cases during follow-up. Statin use was associated with reduced MM-specific mortality (pre-diagnosis use multivariate-adjusted HR, 95% CI: 0.83, 0.71-0.96; 6 months post-diagnosis: 0.73, 0.60-0.89; entire follow-up: 0.65, 0.52-0.80) and (more weakly) with all-cause mortality. Intensity analyses suggested a dose-response; MM-specific mortality decreased with increasing statin intensity in all time windows (eg, 6 months post-diagnosis: low [0.76 (0.56-1.03)], medium [0.73 (0.58-0.92)], high [0.33 (0.08-1.32)] intensity). However, relatively few patients received high intensity treatment, and the trend was statistically significant only for unadjusted pre-diagnosis use. In this large population-based MM cohort, statin use was associated with improved MM-specific survival in both sexes. Randomized prospective studies are warranted to evaluate statins as adjuvant treatment in MM.
引用
- Brånvall E, Ekberg S, Eloranta S, et al. Statin use is associated with improved survival in multiple myeloma: A Swedish population-based study of 4315 patients. Am J Hematol. 2020. PMID: 32141627. doi:10.1002/ajh.25778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。